FierceBiotech

Regulus Announces Completion of Public Offering and Exercise in Full of Overallotment Option

LA JOLLA, Calif., July 23, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...
Business Insider

Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit

SAN DIEGO, May 14, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...
Seeking Alpha

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant ...

SAN DIEGO, June 27, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
FierceBiotech

Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions

LA JOLLA, Calif., Nov. 5, 2012 -- /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting ...
Seeking Alpha

Regulus Therapeutics Strengthens Research & Development Leadership

SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Benzinga.com

Is Regulus Preparing For A Huge Breakout?

Approximately two weeks ago the S&P 500 finally broke through its 2065 resistance. At the same time, the Nasdaq Composite pushed above its 4800 resistance. Expectations at that time would have been ...
Finanznachrichten

Regulus Therapeutics Inc.: Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the ...

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Nasdaq

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Nasdaq

Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer

LA JOLLA, Calif., Aug. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...